Dolutegravir is the first integrase inhibitor available as a dispersible tablet for oral suspension for children weighing at least 3kg and from four weeks of age. The FDA approval is testament to the ...

TRIUMEQ PD is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in children. TRIUMEQ PD contains the prescription medicines Abacavir, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved dolutegravir tablets and dolutegravir tablets for oral suspension to treat HIV infection, ...

Triumeq PD is the first dispersible single tablet regimen containing dolutegravir for children living with HIV The authorisation is an important step to meet ViiV Healthcare’s commitment to bring ...

Otsuka is on course to further expand use of its treatment for pulmonary multidrug resistant tuberculosis (MDR-TB) to children. Europe's Committee for Medicinal Products for Human Use (CHMP) has ...

* VIIV HEALTHCARE -TIVICAY PD, EXTENDED INDICATION OF EXISTING TIVICAY 50MG FILM-COATED TABLET ARE CURRENTLY UNDER REVIEW BY EUROPEAN MEDICINES AGENCY * VIIV HEALTHCARE - DOLUTEGRAVIR IS 1ST INTEGRASE ...

A new sweetened, cherry-flavoured dispersible antimalarial tablet is as effective as the crushed, currently used variety, which needs to be crushed before administration to small children, resulting ...

GPs have been advised to avoid prescribing effervescent, dispersible and soluble formulations of drugs after a study found they were associated with significantly increased risk of heart attacks and ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Riamet Dispersible Tablets contain the active ingredient Artemether ...

Fizzy drug formulations may pose CV risk Taking effervescent medication on a regular basis may increase patients' risk for cardiovascular events due to excess sodium. Effervescent, dispersible and ...

Deborah Waterhouse, CEO of ViiV Healthcare, said: “ I am delighted that our innovative approach to science has enabled us to achieve FDA approval of the first-ever dispersible tablet formulation of ...